Close Menu

NEW YORK (GenomeWeb) – Thermo Fisher Scientific said today that it has signed an agreement with Eli Lilly and Company to develop a companion diagnostic for Lilly's RET kinase inhibitor, LOXO-292.

The companies plan to use Thermo Fisher's Oncomine Dx Target test, a sequencing panel that is approved by the US Food and Drug Administration, to identify non-small cell lung cancer and thyroid cancer patients with RET alterations who might benefit from LOXO-292.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
10

This webinar will provide an overview of how a pathology laboratory validated a 77-gene next-generation sequencing-based liquid biopsy assay.

Oct
24

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.